company background image
PRQR

ProQR Therapeutics NasdaqCM:PRQR Stock Report

Last Price

US$3.15

Market Cap

US$225.0m

7D

16.2%

1Y

-47.0%

Updated

06 Feb, 2023

Data

Company Financials +

ProQR Therapeutics N.V.

NasdaqCM:PRQR Stock Report

Mkt Cap: US$225.0m

PRQR Stock Overview

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders.

PRQR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

ProQR Therapeutics N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ProQR Therapeutics
Historical stock prices
Current Share PriceUS$3.15
52 Week HighUS$6.15
52 Week LowUS$0.53
Beta0.22
1 Month Change-11.76%
3 Month Change240.91%
1 Year Change-46.97%
3 Year Change-62.54%
5 Year Change4.13%
Change since IPO-78.62%

Recent News & Updates

Recent updates

ProQR says EU regulator seeks additional trial for lead candidate

Aug 11

Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Nov 10
Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Investment Case On ProQR Therapeutics Gets More Enticing

Oct 01

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

Aug 04
ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data

Jun 20

It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year

May 13
It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year

ProQR Therapeutics offers a de-risked opportunity: Stifel

May 03

If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%

Mar 08
If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%

Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?

Feb 01
Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?

ProQR concludes enrollment in mid-stage cell therapy trial in a rare eye disorder

Jan 07

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

Dec 28
ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns

Dec 01
A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns

ProQR reports Q3 results

Nov 16

Shareholder Returns

PRQRUS BiotechsUS Market
7D16.2%-0.8%1.7%
1Y-47.0%4.3%-9.6%

Return vs Industry: PRQR underperformed the US Biotechs industry which returned 4.3% over the past year.

Return vs Market: PRQR underperformed the US Market which returned -9.6% over the past year.

Price Volatility

Is PRQR's price volatile compared to industry and market?
PRQR volatility
PRQR Average Weekly Movement22.8%
Biotechs Industry Average Movement12.1%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: PRQR is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week.

Volatility Over Time: PRQR's weekly volatility has increased from 18% to 23% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012182Daniel de Boerhttps://www.proqr.com

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology.

ProQR Therapeutics N.V. Fundamentals Summary

How do ProQR Therapeutics's earnings and revenue compare to its market cap?
PRQR fundamental statistics
Market CapUS$225.02m
Earnings (TTM)-US$77.67m
Revenue (TTM)US$4.25m

53.0x

P/S Ratio

-2.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PRQR income statement (TTM)
Revenue€3.93m
Cost of Revenue€0
Gross Profit€3.93m
Other Expenses€75.88m
Earnings-€71.94m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.01
Gross Margin100.00%
Net Profit Margin-1,829.27%
Debt/Equity Ratio10.3%

How did PRQR perform over the long term?

See historical performance and comparison